Information on the target
Blue Earth Capital is a private equity firm established in 2015, headquartered in Baar, Switzerland. As of August 2026, the firm is an active investor with a diverse portfolio comprising 83 companies, which includes 83 funding rounds and one acquisition. Over the past year, Blue Earth Capital has participated in four funding rounds, demonstrating its commitment to investing in high-potential companies across various sectors.
The firm primarily focuses its investments in companies located in India and the United States, with a portfolio that spans multiple sectors, including Financial Services and Environment Tech. Its most recent investment was a Series B round in Tenet Diagnostics on August 18, 2026, in collaboration with Tata Capital Healthcare Fund.
Industry overview in the target’s specific country
The Drug Retailers (NEC) industry in India has experienced significant growth in recent years, driven by increasing healthcare awareness, rising disposable incomes, and a growing population. The sector is characterized by a mix of organized and unorganized players, with a notable shift towards organized retailing as consumers seek quality and convenience. The Indian government’s initiatives to improve healthcare access and affordability have further bolstered the industry's expansion.
In India, the drug retail market is projected to continue its upward trajectory, fueled by the increasing prevalence of chronic diseases and the demand for over-the-counter medications. The rise of e-pharmacy platforms has also transformed the landscape, allowing consumers to access medications more conveniently and at competitive prices. This digital shift is expected to enhance customer engagement and drive sales growth in the sector.
Moreover, regulatory reforms aimed at streamlining the licensing process for pharmacies and promoting transparency in drug pricing are expected to create a more favorable environment for organized players. As a result, established pharmacy chains are likely to gain market share, while smaller, unorganized retailers may face challenges in competing effectively.
Overall, the Drug Retailers (NEC) industry in India presents a compelling investment opportunity, with strong growth pr…